Custom Synthesis Chemistry Services CRO, Onyx Scientific, Hails the Success of its Solid-State Polymorph Screening Services for Increased Process Development and GMP Synthesis Demand
Onyx Scientific provides custom synthesis chemistry services throughout all stages of a drug-discovery process for phase l and ll clinical studies.

TYNE AND WEAR, ENGLAND, January 05, 2011 /24-7PressRelease/ -- Onyx Scientific, a trusted global chemistry services CRO and leading provider of high justified intermediates and APIs for both phase I and phase II clinical studies, hails the success of its world-class solid-state polymorph screening services for the increased demand for its international GMP-compliant Process Development capability.

Onyx Scientific specialise in Medicinal Chemistry, Process Development, Custom Synthesis, GMP synthesis and Scale-up, in addition to a comprehensive range of Analytical and Solid-State services including automated Salt Selection and Polymorphism studies, with the capability to deliver API scale-up to multi-kilo level and beyond.

CEO, Onyx scientific Ltd, Tony Flynn comments, "The genuine skills and experience required to develop sustainable Process Development are relatively rare. We routinely develop robust, safe and reproducible processes with an emphasis on compound quality, purity and pharmacological properties."

Tony adds, "Our synthetic organic chemistry expertise and automated screening platform enable the rapid evaluation of possible solid-forms and polymorphs for maximum intellectual property generation. We constantly adapt our services to meet the needs of our pharmaceutical and biotech customers with a focus on building long-term customer relationships."

Recognised as the preferred contract research organisation to four of the world's top seven pharmaceutical companies, Onyx offers a unique and flexible chemistry outsourcing experience and enjoys repeat business with more than 150 companies worldwide.

Onyx Scientific is routinely inspected by the MHRA and holds a GMP Certificate for the development and manufacture of Active Pharmaceutical Ingredients (API's). The Onyx facilities, systems and activities comply with the Good Manufacturing Practice requirements referred to in Part II of the EU Guidelines to Good Manufacturing Practice.

Press Release Contact Information:

Sue Jones
Onyx Scientific Ltd
Marketing Communications
Silver, Enterprise Park East
Sunderland, Tyne and Wear
UK SR5 2TQ
Voice: +44 191 516 6516
Fax: +44 191 516 6526
Website: Visit Our Website